Clinical Trial Update: Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating trilaciclib to prevent chemotherapy-induced hematopoietic suppression in patients with recurrent or metastatic head and neck…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• trilaciclib (trilaciclib)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Status: NOT_YET_RECRUITING